Once-weekly insulin vs daily basal insulin
Insulin icodec and insulin efsitora alfa are basal insulins given once a week. Glargine and degludec are basal insulins given once a day. This page brings together our reports on each, and on trials that compared them.
What our reports show
No report compared once-weekly insulin with daily basal insulin directly, so the evidence below cannot be set side by side.
Our report on once-weekly insulin is a regulatory notice, not a trial. The US FDA approved Awiqli (insulin icodec-abae) for patients aged 10 years and older with type 2 diabetes. The paediatric evidence is a single-dose pharmacokinetic study in 18 patients plus modelling. The notice reports no glycaemic outcomes in children. Hypoglycaemia is the most common adverse reaction. The label warns about dosing errors because Awiqli is dosed differently from other insulins.
Our report on basal insulin is a Swedish nationwide observational study. It compared degludec with glargine in people with type 2 diabetes starting insulin. In the trial-eligible cohort, MACE did not differ significantly (risk ratio 1.10; 95% CI 0.91-1.34), but all-cause mortality was lower with degludec (risk ratio 0.75; 95% CI 0.62-0.92). In the trial-ineligible cohort, degludec was associated with a lower risk of MACE (risk ratio 0.80; 95% CI 0.67-0.95). This is registry data, so it shows association, not cause.
These two sources differ in design, patients and endpoints. One is a pharmacokinetic study with modelling in children, with no clinical outcomes reported. The other is a registry comparison of two insulins on cardiovascular and mortality outcomes. The Swedish study did not include a weekly insulin, and the FDA notice did not compare Awiqli with a daily insulin. Neither source can tell you how the two options compare.
Written only from the reports below and checked against them. Updated 14 November 2026.
Studies that looked at both
None of our reports so far has covered a study of both. This list updates itself when one is published.
Once-weekly insulin
- FDA approves once-weekly insulin Awiqli for children with type 2 diabetesRegulatory · 24 October 2026
- EMA committee backs orforglipron (Foundayo) for weight management and type 2 diabetesRegulatory · 18 October 2026
Daily basal insulin
- CDSCO expert committee: Phase III trial of degludec/aspart mix recommendedRegulatory · 31 October 2026
- CDSCO expert committee: trial permission recommended for oral semaglutide, 3 moreRegulatory · 24 October 2026
- Degludec linked to lower all-cause mortality than glargine in Swedish registerCohort study · 21 October 2026
- Orforglipron with insulin glargine: larger HbA1c fall than placebo in phase 3Randomised trial · 11 October 2026
For registered medical practitioners. This page summarises published research and is not advice for individual patients. Last new report 31 October 2026.
Today's Rounds, in your inbox at 8am
The day's reports each morning, and Weekend Rounds on Saturday. Free, no advertising.
Or follow on WhatsApp or Telegram (every report, as it is published), watch on YouTube, listen on Spotify or Apple Podcasts, or follow on LinkedIn. Not sure? Pick one.